1,186
edits
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
__TOC__ | __TOC__ | ||
<h3>Introduction</h3> | <br><h3>Abstract</h3> | ||
After atypical nervous system damage suffered while on duty as a Starfleet security officer, a 26-year-old (Earth Standard) female metagenetic Klingon suffered a loss of prosthetic control concurrent with severe physical discomfort. Due to the extensive nature of the nervous system damage, standard prosthetic control methodologies were discovered to be non-viable. Working in tandem with the primary attending physician, the Engineering team of the USS Veritas (Starfleet Registry NCC-95035) designed, tested and implanted a novel transceiver module which provides positive prosthetic control without further stress on the patient’s nervous system. This module, after proper peer review, will allow for a radical new archetype in prosthetic design and implementation in humanoid subjects. | |||
<br><h3>Introduction</h3> | |||
At present, when attending to cases of extremity loss, Federation physicians have limited options available to them when it comes to limb replacement and subsequent physical therapy. While bio-grafting and ninth-generation cybernetic limbs are versatile and proven therapeutic approaches, they do have limitations and fundamentally rely on the patient’s existing nervous system for functionality. While this is typically viewed favorably as it keeps rejection rates extremely low, there are some cases where typical neuro-servo control apparatuses are non-suitable. While this group has historically been statistically small, it is still a significant underserved patient base. | At present, when attending to cases of extremity loss, Federation physicians have limited options available to them when it comes to limb replacement and subsequent physical therapy. While bio-grafting and ninth-generation cybernetic limbs are versatile and proven therapeutic approaches, they do have limitations and fundamentally rely on the patient’s existing nervous system for functionality. While this is typically viewed favorably as it keeps rejection rates extremely low, there are some cases where typical neuro-servo control apparatuses are non-suitable. While this group has historically been statistically small, it is still a significant underserved patient base. | ||
Line 21: | Line 25: | ||
<br>Prior experimentation with alternate control apparatuses have been hampered by the size of existing components and their suitability for safe installation. This kept most alternates from moving beyond the prototype or early trial stage, and had remained an unresolved challenge for a subset of patients. | <br>Prior experimentation with alternate control apparatuses have been hampered by the size of existing components and their suitability for safe installation. This kept most alternates from moving beyond the prototype or early trial stage, and had remained an unresolved challenge for a subset of patients. | ||
<br><h3>Case Presentation</h3> | <br><h3>Case Presentation</h3> |